Etiology of acute ischaemic cerebrovascular disease associated with rheumatoid arthritis: changes with progression of anti-inflammatory therapy.
Hiroyuki HashimotoM KawamuraT YukamiM IshiharaY BambaS KaneshiroH TsuboiK YamamotoPublished in: European journal of neurology (2018)
With progress in treatment, RA-related inflammation was better suppressed and CRP decreased, but the prevalence of RA amongst acute iCVD patients was unchanged. Strategies for tighter control of inflammation are needed, and a new biomarker may be required in patients using tocilizumab.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- newly diagnosed
- ejection fraction
- liver failure
- oxidative stress
- prognostic factors
- disease activity
- anti inflammatory
- peritoneal dialysis
- intensive care unit
- risk factors
- ankylosing spondylitis
- respiratory failure
- aortic dissection
- patient reported outcomes
- hepatitis b virus
- drug induced
- mechanical ventilation